Moncks Corner

Researchers are evaluating the effectiveness, safety, and tolerability of an oral drug called VX-993 in adults experiencing pain related to Diabetic Peripheral Neuropathy (DPN), a painful condition caused by nerve damage due to diabetes. This Phase 2 study compares VX-993 to pregabalin, a drug commonly used to treat nerve pain, as well as to placebo treatments matched to each drug. Participants will receive tablets of VX-993 or capsules of pregabalin, or matching placebos, in a dose-ranging, randomized, double-blind, parallel design. The study aims to assess responses to these treatments over a set period, focusing on reducing pain intensity associated with DPN. During the 12-week treatment period, participants' daily pain intensity will be regularly measured using a numeric pain rating scale to track changes from the start of the study. Researchers will monitor safety, tolerability, and treatment effects throughout the study. The trial includes adults aged 18 to 80 years with diabetes and chronic nerve pain in their lower limbs due to DPN.